In vitro susceptibility of Escherichia coli strains isolated from urine samples obtained in mainland China to fosfomycin trometamol and other antibiotics: A 9-year surveillance study (2004-2012)

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Lai, Bei ^a,c   Zheng, Bo ^b   Li, Yun ^b   Zhu, Sainan ^b   Tong, Zhaohui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c Beijing Hosptial ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-BACTERIAL AGENTS; CHINA; EPIDEMIOLOGICAL MONITORING; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; TROMETHAMINE; URINE;

EID: 84893169017     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-66     Document Type: Article

References (9)

1. Zheng B, Lv Y. Ministry of health national antimicrobial investigation Net 2010 report: bacterial distribution and resistance in urinary tract infections in male. Chin J Clin Pharmacol 2011, 27(12):905-912.
2. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; M100-S22 2012, Wayne, PA: Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute.
3. Muratani T, Matsumoto T. Bacterial resistance to antimicrobials in urinary isolates. Int J Antimicrob Agents 2004, 24(Suppl 1):S28-S31.
4. Ko KS, Suh JY, Peck KR, Lee MY, Oh WS, Kwon KT, Jung DS, Lee NY, Song JH. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 2007, 58(1):111-115. 10.1016/j.diagmicrobio.2006.11.015, 17300900.
5. Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM, Huang CC, Liu CE, Ko WC, Wang JH, et al. Epidemiology and antimicrobial susceptibility profiles of gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the study for monitoring antimicrobial resistance trends (SMART). Int J Antimicrob Agents 2012, 40(Suppl):S37-S43.
6. Liu HY, Lin HC, Lin YC, Yu SH, Wu WH, Lee YJ. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect 2011, 44(5):364-368. 10.1016/j.jmii.2010.08.012, 21524974.
7. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997, 53(4):637-656. 10.2165/00003495-199753040-00007, 9098664.
8. European Association of Urology, Guidelines on Urological Infections [http://www.uroweb.org/fileadmin/guidelines/Total_file_2013_large_guidelines_prints.pdf].
9. Qiao LD, Zheng B, Chen S, Yang Y, Zhang K, Guo HF, Yang B, Niu YJ, Wang Y, Shi BK, et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open 2013, 3(12):e004157. 10.1136/bmjopen-2013-004157, 3855495, 24309172.